Sort
39,280 grants matching “leukemia”
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2021 · AI
Production Technology for Recombinant Intravenous Immunoglobulin
$1,000,000David Scott Johnson · Gigagen, Inc. · R44 · FY2017 · AI
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$1,000,000Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2020 · CA
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Production Technology for Recombinant Intravenous Immunoglobulin
$1,000,000David Scott Johnson · Gigagen, Inc. · R44 · FY2019 · AI
Comparative Approach to the Hematopoietic Stem Cell
$1,000,000Children'S Hospital Boston · U01 · FY2004 · DK
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2022 · AI
Comparative Approach to the Hematopoietic Stem Cell
$1,000,000Children'S Hospital Boston · U01 · FY2003 · DK
AI-based AML risk stratification using next generation cytogenomics
$1,000,000Stephen Matthew Eacker · Phase Genomics, Inc. · R44 · FY2023 · CA
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2020 · AI
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
$999,999Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2023 · CA
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
$999,999Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2022 · CA
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$999,998Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2021 · CA
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
$999,997Gary G. Altman · Cambium Oncology Llc · R44 · FY2025 · CA
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2022 · CA
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2025 · CA
Human T Cell Lymphotropic Virus Vaccine Development
$999,969Glen N Barber · Stinginn, Llc · R42 · FY2024 · CA
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
$999,628Bernadette McMahon Adair · Keystone Nano, Inc. · R44 · FY2022 · CA
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
$999,628Bernadette McMahon Adair · Keystone Nano, Inc. · R44 · FY2023 · CA
Clinical Development of JS-K for the Treatment of Cancer
$999,423Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2018 · CA
Preventing and treating RSV pneumonia in immunocompromised cancer patients
$999,372Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2021 · CA
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2022 · CA
Clinical Development of JS-K for the Treatment of Cancer
$999,183Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2017 · CA
Center for Integrative Research on Childhood Leukemia and the Environment
$998,999Catherine Metayer · University Of California Berkeley · P50 · FY2015 · ES